Source - RNS
RNS Number : 0146J
Redx Pharma plc
06 September 2016
 

 

AIM: REDX

 

 REDX PHARMA PLC

("Redx" or "the Company")

 

Supply contract agreed with Quay Pharma

for

 expected clinical trial of Porcupine inhibitor

 

Redx, the drug development company, is pleased to announce that it has entered into an agreement with Quay Pharma to manufacture the clinical trial supplies for Redx's Porcupine inhibitor (RXC004), which has the potential to tackle hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers. As previously reported, first-in-human studies for the Porcupine inhibitor are expected to commence in the first quarter of 2017.

 

The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells associated with tumorigenesis, metastasis, recurrence and resistance in several types of cancer. It will have the potential to be taken orally by patients as a once daily dose. 

 

Quay Pharma is a UK-based world leader in contract development, manufacturing and packaging services to the pharmaceutical and biotech industries. Quay Pharma will be formulating the capsules that will be administered in Redx's trial.

 

Neil Murray, CEO of Redx, commented:

 

"We are pleased to confirm that we remain on track to enter the clinical trial phase for our Porcupine program in the first quarter of 2017. Our Porcupine inhibitor is an especially exciting clinical candidate, both scientifically and commercially. This class of drugs has the potential to treat difficult cancer indications, like pancreatic, triple negative breast, and head and neck cancers. Less than 10% of pancreatic cancer patients survive five years from their diagnosis.  The potential for this new class of drugs to tackle such difficult cancers could see a significant advance for patients who have few meaningful treatment options today."

 

Maireadh Pedersen, CEO of Quay Pharma, commented:

 

"We are delighted that Redx has selected Quay Pharma based upon our formulation development expertise, unparalleled flexibility and successful track record of delivering clinical trial supplies on time. We look forward to a successful collaboration with the team at Redx on their lead project in this important indication."

 

For further information, please contact:

 

Redx Pharma Plc

T: 0151 706 4747

Neil Murray, Chief Executive

Company website: redxpharma.com 

 

 

Cantor Fitzgerald Europe (Nomad & Broker)

T: 020 7894 7000

Phil Davies / Michael Reynolds

 

 

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

 

 

 

About Redx Pharma Plc

www.redxpharma.com

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhea, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

About Quay Pharma

http://www.quaypharma.com/

 

Quay Pharma is a world-class contract development and manufacturing organization (CDMO) serving the global pharmaceutical and biotechnology market from MHRA and FDA approved facilities. Quay provides a comprehensive range of services from formulation and analytical development through to clinical trial and commercial manufacturing. Our key differentiators are scientific know-how and expertise in combination with a pragmatic and flexible approach to deliver a tailored solution that is appropriate for the phase of development. Quay has built a reputation for specialising in the formulation of API's that exhibit poor solubility and bio-availability and those which require modified or controlled release and has experience of working with conventional small molecules, NCEs, peptides, antibodies, natural allergens and live bio-therapeutics.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAENSELPKEAF